Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
  • Patent number: 10352933
    Abstract: Detection and quantification of microbial colonization and biofilm formation on orthopedic explants would be important for deciding treatment interventions at the time of surgery. Methods and Systems for such treatments are shown that utilize various steps and kits to quickly generate confocal laser-scanning microscopy (CLSM) images to allow for the detection and quantification. The explants are prepared by applying antibodies of both gram-positive and grain-negative for at least one period of time.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: July 16, 2019
    Assignee: Rhode Island Hospital
    Inventors: Dioscaris Garcia, Christopher T. Born, John Jarrell
  • Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Patent number: 10335496
    Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: July 2, 2019
    Assignee: VelosBio Inc.
    Inventors: Brian Lannutti, Katti Jessen, Thanh-Trang Vo, Jeffry Dean Watkins
  • Patent number: 10329350
    Abstract: The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 25, 2019
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Min-Yuan Chou, Chuan-Chuan Huang, Hsiu-Chuan Li, Ya-Ping Lai
  • Patent number: 10322193
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 18, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10323082
    Abstract: A method of treating tau pathologies, such as Alzheimer's disease, involving the administration of antibodies specific to the amino terminal region of human tau (amino acid residues 6-18 or 184-195) to provide passive immunization. The administration of such antibodies can reduce total tau levels, decrease tau hyperphosphorylation, and improve reference memory. Passive immunization with antibodies targeting the N-terminal projection domain of tau reduces both total and hyperphosphorylated tau was found effective in aged 3×Tg-AD mice, a generally accepted mouse model of Alzheimer's disease and frontotemporal dementia in humans.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: June 18, 2019
    Assignee: THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 10280220
    Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: May 7, 2019
    Assignee: IBC Pharmaceuticals, Inc.
    Inventor: Serengulam V. Govindan
  • Patent number: 10273297
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 30, 2019
    Assignee: ZYMOGENETICS, INC.
    Inventors: Anthony W. Siadak, Shirley A. Rene, Janine M. Bilsborough
  • Patent number: 10273310
    Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 30, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
  • Patent number: 10265414
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: April 23, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10265426
    Abstract: Disclosed herein is a method for preparing a scandium nano-radiopharmaceutical. The method comprises forming a plurality of scandium-encapsulated dendrimers by encapsulating scandium in polyamidoamine (PAMAM) dendrimers with amine surface groups, and forming a scandium nano-radiopharmaceutical by irradiating the plurality of scandium-encapsulated dendrimers by bombarding neutrons toward the scandium-encapsulated dendrimers.
    Type: Grant
    Filed: October 28, 2017
    Date of Patent: April 23, 2019
    Inventors: Navideh Aghaei Amirkhizi, Leila Moghaddam-Banaem, Mitra Athari Allaf, Sodeh Sajadi, Fariba Johari Daha
  • Patent number: 10259868
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 16, 2019
    Assignee: ZYMOGENETICS, INC.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Patent number: 10246515
    Abstract: Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Frederic J. De Sauvage, Brian Biehs
  • Patent number: 10232063
    Abstract: Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: March 19, 2019
    Assignee: Sirtex Medical Limited
    Inventors: Jens Ricke, Holger Amthauer, Oliver Grober
  • Patent number: 10233252
    Abstract: A pH-dependent antibody that binds an antigen with high affinity at a first pH and rapidly dissociates at a second pH, wherein the antigen is a transferrin receptor (TfR), wherein the association at the second pH/the first pH is less than 20%, and wherein the pH-dependent antibody comprises at least two consecutive histidine residues at a single complementarity determining region (CDR) is disclosed.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 19, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric V. Shusta, Benjamin J. Tillotson
  • Patent number: 10226497
    Abstract: A method of treating neurological condition in a subject by administration of a pharmaceutical composition that excludes cardiac glycoside and excludes polysaccharide obtained from Nerium species or Thevetia species. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the pharmaceutical composition to a subject.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 12, 2019
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 10202462
    Abstract: The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease (e.g., cancer) are also encompassed by the invention.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 12, 2019
    Assignee: X-BODY, Inc.
    Inventors: Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
  • Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Patent number: 10202449
    Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: February 12, 2019
    Assignee: XBIOTECH, INC.
    Inventor: John Simard
  • Patent number: 10196439
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Patent number: 10183971
    Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 22, 2019
    Assignee: The Feinstein Institute For Medical Research
    Inventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
  • Patent number: 10159690
    Abstract: Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: December 25, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Su Young Chae, Sunghyun Kim, Sang Ok Song, Jae Il Lee
  • Patent number: 10155803
    Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 18, 2018
    Assignee: ZYMEWORKS INC.
    Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
  • Patent number: 10145849
    Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of SEQ ID NO: 1, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: December 4, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
  • Patent number: 10138296
    Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
  • Patent number: 10124070
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Patent number: 10125194
    Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 13, 2018
    Assignee: PHARMABCINE INC.
    Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
  • Patent number: 10125183
    Abstract: The present invention provides a decoy peptide or polypeptide capable of inhibiting the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1), and a pharmaceutical composition, containing the decoy peptide or polypeptide as an active ingredient, for preventing or treating cancer or an angiogenic disease. Furthermore, the present invention provides a method for screening a material for preventing or treating cancer or an angiogenic disease. According to the present invention, it is worth noting that the decoy peptide or polypeptide of the present invention induces apoptosis through the inhibition of the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1); reduces migration and adhesion of endothelial cells; significantly reduces vascular induction, survival, and growth.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 13, 2018
    Assignee: Curacle Co., Ltd.
    Inventors: Young Guen Kwon, Hyo Jin Park
  • Patent number: 10093745
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a mutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 9, 2018
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • Patent number: 10064925
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • Patent number: 10060908
    Abstract: Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunization and therapy of these diseases and conditions are provided.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: August 28, 2018
    Assignee: MEDIRISTA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Patent number: 10059765
    Abstract: The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: August 28, 2018
    Assignee: INNATE PHARMA S.A.
    Inventors: Andrea Velardi, Francois Romagne
  • Patent number: 10059768
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: August 28, 2018
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 10046050
    Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: August 14, 2018
    Assignee: UNIVERSITY OF TENESSEE RESEARCH FOUNDATION
    Inventors: Jonathan S. Wall, Stephen J. Kennel, James S. Foster
  • Patent number: 10036070
    Abstract: The invention relates to methods of typing a sample from a colorectal cancer patient based on the levels of RNA expression products in a cancer cell of the patient. The invention further relates to methods for determining a strategy for treatment of a patient suffering from colorectal cancer, and to methods for assigning treatment to a patient suffering from colorectal cancer.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: July 31, 2018
    Assignee: AGENDIA N.V.
    Inventors: Paul Roepman, Iris Simon, Tian Sun
  • Patent number: 10023629
    Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition comprising the antibody.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: July 17, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
  • Patent number: 10018633
    Abstract: Disclosed are methods and compositions for the detection of one or more different types of cellular biomarkers in a biological sample, and in particular, methods and compositions for the rapid, one-step, highly-cell specific detection of circulating tumor cells from minute quantities of mammalian biological fluids, including, for example, from a single drop of human blood. In certain embodiments, distinctly-labeled, multi-aptamer detection reagents are provided for detecting and quantitating selected cancer cells in clinical samples such as patient specimens and/or tissues. Aptamer-based imaging methodologies are also provided for use in a variety of diagnostic assay protocols.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 10, 2018
    Assignee: The Methodist Hospital Research Institute
    Inventor: Youli Zu
  • Patent number: 10011874
    Abstract: Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: July 3, 2018
    Assignee: Novartis AG
    Inventors: Giordano Caponigro, Vesselina Cooke, Scott Delach, Joshua Korn, Manav Korpal, Wenlai Zhou, Ping Zhu
  • Patent number: 9994643
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 9988447
    Abstract: Glycated hemoglobin (HbA1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 5, 2018
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Patent number: 9963517
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 8, 2018
    Assignees: Genentech, Inc., University of Turku
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Patent number: 9956562
    Abstract: The invention features devices and methods for the deterministic separation of particles. Exemplary methods include the enrichment of a sample in a desired particle or the alteration of a desired particle in the device. The devices and methods are advantageously employed to enrich for rare cells, e.g., fetal cells, present in a sample, e.g., maternal blood and rare cell components, e.g., fetal cell nuclei. The invention further provides a method for preferentially lysing cells of interest in a sample, e.g., to extract clinical information from a cellular component, e.g., a nucleus, of the cells of interest. In general, the method employs differential lysis between the cells of interest and other cells (e.g., other nucleated cells) in the sample.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: May 1, 2018
    Assignees: The General Hospital Corporation, GPB Scientific, LLC
    Inventors: Lotien Richard Huang, Thomas A. Barber, Bruce L. Carvalho, Ravi Kapur, Paul Vernucci, Mehmet Toner, Zihua Wang
  • Patent number: 9951377
    Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: April 24, 2018
    Assignees: APPLIED BIOSYSTEMS, LLC, DAKO DENMARK A/S
    Inventors: Kirsten Vang Nielson, Jens Hyldig-Nielsen, Brett F. Williams
  • Patent number: 9943610
    Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 17, 2018
    Assignees: BioAlliance C.V., AbGenomics International Inc.
    Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang
  • Patent number: 9931401
    Abstract: The present invention provides a combination of an antibody binding to a fibroblast growth factor receptor, and another agent.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 3, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Atsushi Urano, Yasuki Kamai
  • Patent number: 9915647
    Abstract: The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., PFOs) for measuring intracellular mitochondrial activity.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 13, 2018
    Assignees: BAYSTATE MEDICAL CENTER, INC., UNIVERSITY OF MASSACHUSETTS
    Inventors: Nagendra Yadava, Alejandro Pablo Heuck, Chul Kim
  • Patent number: 9914780
    Abstract: The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 13, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Lishan Su
  • Patent number: 9872923
    Abstract: A method of producing an immunoligand/payload conjugate can encompass conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 23, 2018
    Assignee: NBE THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Patent number: 9862943
    Abstract: Long noncoding RNAs (lncRNAs) are identified that enhance pluripotency reprogramming of somatic cells as well as differentiation of pluripotent cells. Induced pluripotent stem (iPS) cell generation from somatic cells leads to the upregulation and downregulation of identified lncRNAs. The modulation of these lncRNAs are capable of enhancing pluripotency of somatic cells as well as enhancing differentiation of a pluripotent cell.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: January 9, 2018
    Assignee: California Institute of Technology
    Inventors: Daniel H. Kim, Barbara J. Wold